Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants.
about
p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwanp73 as a pharmaceutical target for cancer therapyTP63 and TP73 in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy.Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor geneHomozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese populationTP53 Pro72 allele is enriched in oral tongue cancer and frequently mutated in esophageal cancer in India.Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer.Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian patient population.Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotesp53 codon 72 polymorphism as a progression index for bladder cancer.The determination of genetic markers of age-related cancer pathologies in populations from Kazakhstan.Genotype misclassification in genetic association studies of the rs1042522 TP53 (Arg72Pro) polymorphism: a systematic review of studies of breast, lung, colorectal, ovarian, and endometrial cancerAssociation of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression.Expression of pAkt affects p53 codon 72 polymorphism-based prediction of response to radiotherapy in nasopharyngeal carcinoma.Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment.Genetic Modifiers of the p53 Pathway.Association of p53 and p21 polymorphisms with prostate cancerNo association between TP53 Arg72Pro polymorphism and ovarian cancer risk: evidence from 10113 subjects.[Role of the genetic polymorphism of p53 (codon 72) gene in colorectal cancer].Characterization of the p53 mutants ability to inhibit p73β transactivation using a yeast-based functional assay
P2860
Q28384167-37604DA8-4FBE-4EED-8D07-4A810C95EBCBQ28611414-BC4394C2-6563-4571-B2F7-28A44AE769DEQ33358710-B9A16184-83C3-46E1-85FC-07798C7F52FEQ34025309-EE50F0F2-5225-4797-A024-C8FB86105B26Q34382727-8C4180FB-0ECE-4D73-8393-64A077BCA67DQ34601749-1B0DA265-3EFE-4DD8-82A3-754DA5D5CD27Q34928345-B8ACA190-B890-40B8-AD1F-D3991D65B965Q35984539-149C91D7-CE2E-4DEB-A290-BB52AD3397B8Q36624424-C2611359-0590-48D8-98AE-E85FCB0499F8Q36642834-62570F71-19B7-45A9-A6B4-AA6C78A12CABQ36810210-014E1C46-4F35-42BD-8D24-3363B92483B2Q36911839-790C0B95-2BAD-4354-B86F-60C936AF890BQ36965817-68472E69-631D-4C01-8665-85B32720FEE6Q37037859-48B310E3-D545-4A4A-87C0-C9AEC6B8D03CQ37293815-F54C304F-8102-43DF-8BB5-C1AD26179670Q38796076-5D34036F-EA11-4D17-B37A-339E52DF9796Q41990517-E78D815D-182E-4B1E-A2F8-E802F9C7CB7CQ49216581-86845FBC-6075-4047-9710-C570F95FDEFBQ54601634-4EF5E4ED-A1DA-44F2-9D4B-8E8CDB1E5A39Q58416386-AB46EC8D-9F24-4612-9B3D-99E134F89675
P2860
Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Inactivate the remaining p53 a ...... but not transdominant mutants.
@ast
Inactivate the remaining p53 a ...... but not transdominant mutants.
@en
type
label
Inactivate the remaining p53 a ...... but not transdominant mutants.
@ast
Inactivate the remaining p53 a ...... but not transdominant mutants.
@en
prefLabel
Inactivate the remaining p53 a ...... but not transdominant mutants.
@ast
Inactivate the remaining p53 a ...... but not transdominant mutants.
@en
P2093
P356
P1433
P1476
Inactivate the remaining p53 a ...... but not transdominant mutants.
@en
P2093
Furuuchi K
Matsumoto J
Mitsumoto Y
Moriuchi T
Takahashi M
P304
P356
10.1093/CARCIN/22.3.515
P407
P577
2001-03-01T00:00:00Z